Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1/PHASE2
Total Enrollment
160 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-11-11
Study Completion Date
2030-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Neuroblastoma is one of the most common solid childhood tumours, and a major cause of cancer-related death in children. More than 1200 children/young adults a year are diagnosed in USA and Europe. Around 600 of these cases are considered high-risk, which means the cancer is more difficult to treat successfully. Despite improvements in survival over recent decades, a significant proportion of patients with high-risk neuroblastoma have disease that does not respond to standard treatments (refractory neuroblastoma) or comes back after completion of standard frontline treatment (relapsed neuroblastoma). Therefore, there is a need to develop new treatment strategies and test new drugs to improve outcomes for children with neuroblastoma.
Aims Of The BEACON2 Trial
* To improve survival for patients with relapsed neuroblastoma by developing new treatment combinations
* To evaluate new treatment combinations in relapsed neuroblastoma, within a phase I/II trial that can impact clinical practice, while also allowing dose confirmation for new promising combinations
* To evaluate the safety, activity, efficacy and impact on quality of life of these new treatment combinations in relapsed neuroblastoma patients
* To improve our understanding of relapsed neuroblastoma biology and advance the development of targeted therapies using biomarkers, by conducting a comprehensive biomarker sample collection.
Trial Design BEACON2 is a randomised phase I/phase II, open label, international trial. The trial will have two tiers: Tier 1 will be the main randomisation for two treatment arms initially. Participants will be randomised at trial entry to receive one of the available regimens, treatment A or treatment B. Tier 2 will include smaller dose expansion/confirmation cohorts for more novel experimental treatment combinations (Arm C and future arms), with the potential for them to be moved to Tier 1.
Current Tier 1 (Randomisation Tier) Treatment Arms in the BEACON2 Trial:
Arm A: dbIT Treatment with dinutuximab beta, irinotecan, and temozolomide, 3 weekly x12 cycles Arm B: BIT Treatment with bevacizumab, irinotecan, and temozolomide, 3 weekly x12 cycles
Current Tier 2 (Registration Only Tier) Treatment Arms in the BEACON2 Trial:
Arm C: dbBIT Treatment with dinutuximab beta, bevacizumab, irinotecan, and temozolomide, 3 weekly x12 cycles
Patient Population and Sample Size Patients aged ≥1 years of age with relapsed neuroblastoma. For each arm in Tier 1, up to 75 patients will be recruited to complete phase 2 investigations. For each arm in Tier 2, 10 patients will be recruited to complete phase I investigations. Approximately 160 participants are initially planned, 75 in each arm of Tier 1 and 10 participants for one dose-confirmation cohort in Tier 2.
The study is expected to recruit patients for 3 years, and then finish patient follow-up after an additional 5 years.
Translational Sub-study / Biological Studies
It is standard of care for patients diagnosed with relapsed neuroblastoma to:
* Have had a tumour sample collected at point of initial diagnosis (either during biopsy or surgery)
* Have bloods collected before they start and during treatment for their relapsed neuroblastoma
* Have a bone aspirate/trephine procedure in order to help confirm relapse. These samples provide very important opportunities for further research, and the study investigators would like to make full use of these opportunities by collecting the analysis already performed on these samples and collect some additional samples (at the same time as the standard ones) to learn and understand more about neuroblastoma and its treatment. Samples will undergo research analysis at the national SIOPEN reference laboratories.
Aims Of The BEACON2 Trial
* To improve survival for patients with relapsed neuroblastoma by developing new treatment combinations
* To evaluate new treatment combinations in relapsed neuroblastoma, within a phase I/II trial that can impact clinical practice, while also allowing dose confirmation for new promising combinations
* To evaluate the safety, activity, efficacy and impact on quality of life of these new treatment combinations in relapsed neuroblastoma patients
* To improve our understanding of relapsed neuroblastoma biology and advance the development of targeted therapies using biomarkers, by conducting a comprehensive biomarker sample collection.
Trial Design BEACON2 is a randomised phase I/phase II, open label, international trial. The trial will have two tiers: Tier 1 will be the main randomisation for two treatment arms initially. Participants will be randomised at trial entry to receive one of the available regimens, treatment A or treatment B. Tier 2 will include smaller dose expansion/confirmation cohorts for more novel experimental treatment combinations (Arm C and future arms), with the potential for them to be moved to Tier 1.
Current Tier 1 (Randomisation Tier) Treatment Arms in the BEACON2 Trial:
Arm A: dbIT Treatment with dinutuximab beta, irinotecan, and temozolomide, 3 weekly x12 cycles Arm B: BIT Treatment with bevacizumab, irinotecan, and temozolomide, 3 weekly x12 cycles
Current Tier 2 (Registration Only Tier) Treatment Arms in the BEACON2 Trial:
Arm C: dbBIT Treatment with dinutuximab beta, bevacizumab, irinotecan, and temozolomide, 3 weekly x12 cycles
Patient Population and Sample Size Patients aged ≥1 years of age with relapsed neuroblastoma. For each arm in Tier 1, up to 75 patients will be recruited to complete phase 2 investigations. For each arm in Tier 2, 10 patients will be recruited to complete phase I investigations. Approximately 160 participants are initially planned, 75 in each arm of Tier 1 and 10 participants for one dose-confirmation cohort in Tier 2.
The study is expected to recruit patients for 3 years, and then finish patient follow-up after an additional 5 years.
Translational Sub-study / Biological Studies
It is standard of care for patients diagnosed with relapsed neuroblastoma to:
* Have had a tumour sample collected at point of initial diagnosis (either during biopsy or surgery)
* Have bloods collected before they start and during treatment for their relapsed neuroblastoma
* Have a bone aspirate/trephine procedure in order to help confirm relapse. These samples provide very important opportunities for further research, and the study investigators would like to make full use of these opportunities by collecting the analysis already performed on these samples and collect some additional samples (at the same time as the standard ones) to learn and understand more about neuroblastoma and its treatment. Samples will undergo research analysis at the national SIOPEN reference laboratories.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Temozolomide in Treating Young Patients With High-Risk Relapsed or Refractory Neuroblastoma
NCT00276679
Neuroblastoma
COMPLETED
PHASE2
Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma
NCT01467986
Neuroblastoma Recurrent
COMPLETED
PHASE2
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
NCT03794349
High Risk Neuroblastoma
Recurrent Neuroblastoma
Refractory Neuroblastoma
ACTIVE_NOT_RECRUITING
PHASE2
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
NCT06995872
Neuroblastoma
RECRUITING
PHASE1
Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma
NCT00311584
Neuroblastoma
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Relapsed Neuroblastoma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Multi Arm Multi Stage (MAMS) design
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A: dinutuximab, irinotecan and temozolomide (dbIT)
Group Type
ACTIVE_COMPARATOR
Dinutuximab beta
Intervention Type
DRUG
Dinutuximab beta
Irinotecan (drug)
Intervention Type
DRUG
Irinotecan
Topotecan
Intervention Type
DRUG
Topotecan
Temozolomide (TMZ)
Intervention Type
DRUG
Temozolomide capsule
Temozolomide (TMZ)
Intervention Type
DRUG
Temozolomide liquid suspension
Arm B: bevacizumab, irinotecan and temozolomide (BIT)
Group Type
EXPERIMENTAL
Bevacizumab
Intervention Type
DRUG
Bevacizumab
Irinotecan (drug)
Intervention Type
DRUG
Irinotecan
Topotecan
Intervention Type
DRUG
Topotecan
Temozolomide (TMZ)
Intervention Type
DRUG
Temozolomide capsule
Temozolomide (TMZ)
Intervention Type
DRUG
Temozolomide liquid suspension
Arm C: dinutuximab, bevacizumab, irinotecan and temozolomide (dbBIT)
Group Type
EXPERIMENTAL
Bevacizumab
Intervention Type
DRUG
Bevacizumab
Dinutuximab beta
Intervention Type
DRUG
Dinutuximab beta
Irinotecan (drug)
Intervention Type
DRUG
Irinotecan
Topotecan
Intervention Type
DRUG
Topotecan
Temozolomide (TMZ)
Intervention Type
DRUG
Temozolomide capsule
Temozolomide (TMZ)
Intervention Type
DRUG
Temozolomide liquid suspension
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bevacizumab
Bevacizumab
Intervention Type
DRUG
Dinutuximab beta
Dinutuximab beta
Intervention Type
DRUG
Irinotecan (drug)
Irinotecan
Intervention Type
DRUG
Topotecan
Topotecan
Intervention Type
DRUG
Temozolomide (TMZ)
Temozolomide capsule
Intervention Type
DRUG
Temozolomide (TMZ)
Temozolomide liquid suspension
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Disease specific
* Histologically proven neuroblastoma as per International Neuroblastoma Staging System (INSS)\[1\] definition
* High risk relapsed neuroblastoma (relapsed or progressed after being defined as High Risk at any time following diagnosis or progressed/relapsed as high-risk neuroblastoma)
* Measurable disease by cross sectional imaging or evaluable disease (uptake on MIBG scan with or without bone marrow histology), as per INRC \[2, 3\]. Participants with only bone marrow detectable disease (bone marrow aspirate or trephine) are NOT eligible for the study General
* Age ≥1 year
* Signed informed consent from participant, parent or guardian Performance and organ function
* Performance Status
o Lansky (for patients ≤12 years of age) or Karnofsky (for those \>12) ≥ 50%, (Participants who are unable to walk because of paralysis, but who are able to sit upright unassisted in a wheelchair, will be considered ambulatory for the purpose of assessing performance score)
* Life expectancy of ≥12 weeks
* Bone marrow function (within 72 hours prior to randomisation):
* Platelets ≥ 50 x 109/L (unsupported for 72 hours)
* ANC ≥ 0.50 x 109/L (no G-CSF support for 72 hours)
* Haemoglobin \> 8 g/dL (transfusions allowed)
* Renal function (within 72 hours prior to randomisation):
* Absence of clinically significant proteinuria (either early morning urine dipstick ≤ 2+) or if dipstick urinalysis shows \> 2+ proteinuria, protein: creatinine (Pr/Cr) ratio must be \< 0.5 or a 24 hour protein excretion must be \< 0.5g
* Serum creatinine ≤ 1.5 ULN for age, if higher, a measured GFR (radioisotope or 24 hour urine calculated creatinine clearance) must be ≥ 60 ml/min/1.73 m2
* Liver function (within 72 hours prior to randomisation):
o Absence of clinically significant signs of liver dysfunction. AST or ALT ≤ 3.0 ULN and total bilirubin ≤ 1.5 ULN. In patients with liver metastases, AST or ALT ≤ 5 ULN and total bilirubin ≤ 2.5 ULN is allowed.
* Coagulation:
* Participants must not have an active uncontrolled coagulopathy.
* Anticoagulation is permitted as long as the INR or APTT is within therapeutic limits (according to the medical standard of the institution) and the participant has been on a stable dose of anticoagulants for at least two weeks at the time of study enrolment.
* Blood pressure below 95th centile for age and sex. Participants ≥18 years of age should have a blood pressure ≤150/90 mmHg (within 72 hours prior to randomisation). Use of antihypertensive medication is permitted.
• More than one relapse event or ineligible for Tier 1.
NB- The following previous treatments are allowed provided that the principal investigator expects a favourable benefit/risk assessment (e.g. patients could derive potential benefit from the Tier 2 combination):
* bevacizumab,
* any anti-GD2 antibody given with chemotherapy ('chemo-immunotherapy')
* previous treatment with temozolomide with irinotecan
* Histologically proven neuroblastoma as per International Neuroblastoma Staging System (INSS)\[1\] definition
* High risk relapsed neuroblastoma (relapsed or progressed after being defined as High Risk at any time following diagnosis or progressed/relapsed as high-risk neuroblastoma)
* Measurable disease by cross sectional imaging or evaluable disease (uptake on MIBG scan with or without bone marrow histology), as per INRC \[2, 3\]. Participants with only bone marrow detectable disease (bone marrow aspirate or trephine) are NOT eligible for the study General
* Age ≥1 year
* Signed informed consent from participant, parent or guardian Performance and organ function
* Performance Status
o Lansky (for patients ≤12 years of age) or Karnofsky (for those \>12) ≥ 50%, (Participants who are unable to walk because of paralysis, but who are able to sit upright unassisted in a wheelchair, will be considered ambulatory for the purpose of assessing performance score)
* Life expectancy of ≥12 weeks
* Bone marrow function (within 72 hours prior to randomisation):
* Platelets ≥ 50 x 109/L (unsupported for 72 hours)
* ANC ≥ 0.50 x 109/L (no G-CSF support for 72 hours)
* Haemoglobin \> 8 g/dL (transfusions allowed)
* Renal function (within 72 hours prior to randomisation):
* Absence of clinically significant proteinuria (either early morning urine dipstick ≤ 2+) or if dipstick urinalysis shows \> 2+ proteinuria, protein: creatinine (Pr/Cr) ratio must be \< 0.5 or a 24 hour protein excretion must be \< 0.5g
* Serum creatinine ≤ 1.5 ULN for age, if higher, a measured GFR (radioisotope or 24 hour urine calculated creatinine clearance) must be ≥ 60 ml/min/1.73 m2
* Liver function (within 72 hours prior to randomisation):
o Absence of clinically significant signs of liver dysfunction. AST or ALT ≤ 3.0 ULN and total bilirubin ≤ 1.5 ULN. In patients with liver metastases, AST or ALT ≤ 5 ULN and total bilirubin ≤ 2.5 ULN is allowed.
* Coagulation:
* Participants must not have an active uncontrolled coagulopathy.
* Anticoagulation is permitted as long as the INR or APTT is within therapeutic limits (according to the medical standard of the institution) and the participant has been on a stable dose of anticoagulants for at least two weeks at the time of study enrolment.
* Blood pressure below 95th centile for age and sex. Participants ≥18 years of age should have a blood pressure ≤150/90 mmHg (within 72 hours prior to randomisation). Use of antihypertensive medication is permitted.
• More than one relapse event or ineligible for Tier 1.
NB- The following previous treatments are allowed provided that the principal investigator expects a favourable benefit/risk assessment (e.g. patients could derive potential benefit from the Tier 2 combination):
* bevacizumab,
* any anti-GD2 antibody given with chemotherapy ('chemo-immunotherapy')
* previous treatment with temozolomide with irinotecan
Exclusion Criteria
* • Known contraindication or hypersensitivity to:
* Any study drug or component of the formulation
* Chinese hamster ovary products or other recombinant human or humanised antibodies.
* Participants with mild previous hypersensitivity reactions to anti-GD2 antibodies may be included, but those with severe (or G4) hypersensitivity reactions to anti-GD2 antibodies will be excluded.
* Clinically significant neurological toxicity, uncontrolled seizures or objective peripheral neuropathy (\> grade 2). (Unresolved neurological deficits from previous spinal cord compression or surgeries are acceptable). Participants with previous ≥ Grade 3 motor neurotoxicity secondary to anti-GD2 are excluded, even if recovered
* Prior severe arterial thrombo-embolic events (e.g. cardiac ischemia, cerebral vascular accident, peripheral arterial thrombosis) or any ongoing arterial thrombo-embolic events
* A history of (noninfectious) pneumonitis requiring steroids, or current pneumonitis.
* Patients that are allergic to all therapies for Pnemocystis jirovecii pneumonia and can thus not receive prophylaxis for PJP
* Uncontrolled infection
* Inadequate recovery from prior surgery with ongoing ≥ Grade 3 surgical complications. Grade ≥ 2 wound dehiscence.
* Recent surgical procedures (at start of trial treatment). Patient can be randomised up to 48hr prior to these periods being completed provided that trial treatment only starts after complying with all of them:
* Core biopsies within previous 24hr
* Open excisional biopsies within previous 48hr
* Major surgery within previous 2 weeks
* Bone marrow aspirates/trephines, within previous 48hr
* Tunnelled central line insertion within previous 48hr
• Washout from prior treatments (at start of trial treatment):
* Chemotherapy within previous 2 weeks (1 week for oral metronomic chemotherapy regimens)
* Any anti-GD2 therapy within previous 2 weeks
* Craniospinal radiotherapy or MIBG therapy within previous 6 weeks
* Radiotherapy to the tumour bed within previous 2 weeks (no washout for palliative radiotherapy)
* Myeloablative therapy with haematopoietic stem cell rescue (autologous stem cell transplant) within previous 8 weeks
* Allogeneic stem cell transplant within previous 12 weeks (with absence of active ≥ G2 acute GVHD)
* 14 days or 5 half-lives (whichever occurs later) from last administration of an IMP in an IMP-trial
* Bleeding metastases (participants with CNS metastases can be enrolled as long as the metastases are not bleeding). At least 6 months from any ≥ G3 haemoptysis or pulmonary haemorrhage
* Use of enzyme inducing anticonvulsants within 72hr of start of trial treatment
* Conditions that increase the risk of bevacizumab-related toxicities:
* History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e. in the absence of therapeutic anticoagulation)
* History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess or active gastrointestinal bleeding within 6 months prior to study enrolment
* Current chronic intestinal inflammatory disease/bowel obstruction
* Intolerance to galactose and fructose, lactase deficiency, and/or defect of absorption of galactose and fructose
* Males or females of reproductive potential may not participate unless they agree to use a highly effective method of birth control, i.e. with a failure rate of less than 1% per year, (e.g. implants, injectables, combined oral contraceptives, IUDs, sexual abstinence or vasectomised partner), for the duration of study therapy and for up to 6 months after the last dose of trial drugs. A negative urine or serum pregnancy test must be obtained within 72 hours prior to dosing in females who are post-menarche.
* Pregnant or lactating participant
* Live or live-attenuated vaccines given within previous 28 days prior to study enrolment
* Any uncontrolled medical condition that poses an additional risk to the participant
* More than one relapse/progression event after the start of high risk neuroblastoma therapy
* Previous treatments that are not allowed
* Bevacizumab for relapsed neuroblastoma. Patients who have received BIT for refractory disease are not excluded, providing no progression of disease during this treatment occurred
* Treatment with any anti-GD2 antibody given with chemotherapy ('chemo-immunotherapy') for treatment of relapsed neuroblastoma. Prior treatment with chemo-immunotherapy for refractory disease is allowed, provided no disease progression during this therapy.
* Any study drug or component of the formulation
* Chinese hamster ovary products or other recombinant human or humanised antibodies.
* Participants with mild previous hypersensitivity reactions to anti-GD2 antibodies may be included, but those with severe (or G4) hypersensitivity reactions to anti-GD2 antibodies will be excluded.
* Clinically significant neurological toxicity, uncontrolled seizures or objective peripheral neuropathy (\> grade 2). (Unresolved neurological deficits from previous spinal cord compression or surgeries are acceptable). Participants with previous ≥ Grade 3 motor neurotoxicity secondary to anti-GD2 are excluded, even if recovered
* Prior severe arterial thrombo-embolic events (e.g. cardiac ischemia, cerebral vascular accident, peripheral arterial thrombosis) or any ongoing arterial thrombo-embolic events
* A history of (noninfectious) pneumonitis requiring steroids, or current pneumonitis.
* Patients that are allergic to all therapies for Pnemocystis jirovecii pneumonia and can thus not receive prophylaxis for PJP
* Uncontrolled infection
* Inadequate recovery from prior surgery with ongoing ≥ Grade 3 surgical complications. Grade ≥ 2 wound dehiscence.
* Recent surgical procedures (at start of trial treatment). Patient can be randomised up to 48hr prior to these periods being completed provided that trial treatment only starts after complying with all of them:
* Core biopsies within previous 24hr
* Open excisional biopsies within previous 48hr
* Major surgery within previous 2 weeks
* Bone marrow aspirates/trephines, within previous 48hr
* Tunnelled central line insertion within previous 48hr
• Washout from prior treatments (at start of trial treatment):
* Chemotherapy within previous 2 weeks (1 week for oral metronomic chemotherapy regimens)
* Any anti-GD2 therapy within previous 2 weeks
* Craniospinal radiotherapy or MIBG therapy within previous 6 weeks
* Radiotherapy to the tumour bed within previous 2 weeks (no washout for palliative radiotherapy)
* Myeloablative therapy with haematopoietic stem cell rescue (autologous stem cell transplant) within previous 8 weeks
* Allogeneic stem cell transplant within previous 12 weeks (with absence of active ≥ G2 acute GVHD)
* 14 days or 5 half-lives (whichever occurs later) from last administration of an IMP in an IMP-trial
* Bleeding metastases (participants with CNS metastases can be enrolled as long as the metastases are not bleeding). At least 6 months from any ≥ G3 haemoptysis or pulmonary haemorrhage
* Use of enzyme inducing anticonvulsants within 72hr of start of trial treatment
* Conditions that increase the risk of bevacizumab-related toxicities:
* History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e. in the absence of therapeutic anticoagulation)
* History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess or active gastrointestinal bleeding within 6 months prior to study enrolment
* Current chronic intestinal inflammatory disease/bowel obstruction
* Intolerance to galactose and fructose, lactase deficiency, and/or defect of absorption of galactose and fructose
* Males or females of reproductive potential may not participate unless they agree to use a highly effective method of birth control, i.e. with a failure rate of less than 1% per year, (e.g. implants, injectables, combined oral contraceptives, IUDs, sexual abstinence or vasectomised partner), for the duration of study therapy and for up to 6 months after the last dose of trial drugs. A negative urine or serum pregnancy test must be obtained within 72 hours prior to dosing in females who are post-menarche.
* Pregnant or lactating participant
* Live or live-attenuated vaccines given within previous 28 days prior to study enrolment
* Any uncontrolled medical condition that poses an additional risk to the participant
* More than one relapse/progression event after the start of high risk neuroblastoma therapy
* Previous treatments that are not allowed
* Bevacizumab for relapsed neuroblastoma. Patients who have received BIT for refractory disease are not excluded, providing no progression of disease during this treatment occurred
* Treatment with any anti-GD2 antibody given with chemotherapy ('chemo-immunotherapy') for treatment of relapsed neuroblastoma. Prior treatment with chemo-immunotherapy for refractory disease is allowed, provided no disease progression during this therapy.
Minimum Eligible Age
1 Year
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Birmingham
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sydney Children's Hospital (SCH)
Sydney, , Australia
Site Status
NOT_YET_RECRUITING
St. Anna Children´s Hospital
Vienna, , Austria
Site Status
NOT_YET_RECRUITING
Cliniques Universitaires Saint-Luc (CUSL)
Brussels, , Belgium
Site Status
NOT_YET_RECRUITING
Starship Children's Hospital (SSH)
Auckland, , New Zealand
Site Status
NOT_YET_RECRUITING
Royal Aberdeen Children's Hospital
Aberdeen, , United Kingdom
Site Status
RECRUITING
Royal Belfast Hospital for Sick Children
Belfast, , United Kingdom
Site Status
NOT_YET_RECRUITING
Birmingham Children's Hospital
Birmingham, , United Kingdom
Site Status
RECRUITING
Bristol Royal Hospital for Children
Bristol, , United Kingdom
Site Status
RECRUITING
Addenbrookes Hospital
Cambridge, , United Kingdom
Site Status
RECRUITING
Children's Hospital for Wales
Cardiff, , United Kingdom
Site Status
RECRUITING
Royal Hospital for Sick Children
Edinburgh, , United Kingdom
Site Status
NOT_YET_RECRUITING
Royal Hospital for Children
Glasgow, , United Kingdom
Site Status
NOT_YET_RECRUITING
Leeds General Infirmary
Leeds, , United Kingdom
Site Status
RECRUITING
Alder Hey Hospital
Liverpool, , United Kingdom
Site Status
RECRUITING
Great Ormond Street Hospital
London, , United Kingdom
Site Status
RECRUITING
University College London Hospital
London, , United Kingdom
Site Status
NOT_YET_RECRUITING
Royal Manchester Children's Hospital
Manchester, , United Kingdom
Site Status
RECRUITING
Royal Victoria Infirmary
Newcastle upon Tyne, , United Kingdom
Site Status
RECRUITING
Nottingham Children's Hospital
Nottingham, , United Kingdom
Site Status
NOT_YET_RECRUITING
John Radcliffe Hospital
Oxford, , United Kingdom
Site Status
NOT_YET_RECRUITING
Sheffield Children's Hospital
Sheffield, , United Kingdom
Site Status
RECRUITING
Southampton General Hospital
Southampton, , United Kingdom
Site Status
RECRUITING
Royal Marsden Hospital
Sutton, , United Kingdom
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Australia
Austria
Belgium
New Zealand
United Kingdom
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
Principal Investigator
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993 Aug;11(8):1466-77. doi: 10.1200/JCO.1993.11.8.1466.
Reference Type
BACKGROUND
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RG_22-136
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
NCT00436852
COMPLETED
PHASE2
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
NCT01767194
COMPLETED
PHASE2
Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors
NCT00024284
COMPLETED
PHASE1
Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children
NCT07318831
NOT_YET_RECRUITING
PHASE2
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor
NCT00003211
COMPLETED
PHASE2
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
NCT00138216
COMPLETED
PHASE1
Topotecan, Vincristine, and Doxorubicin in Treating Young Patients With Refractory Stage 4 Neuroblastoma
NCT00392340
UNKNOWN
PHASE2
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
NCT01217437
COMPLETED
PHASE2
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
NCT00077454
COMPLETED
PHASE1
Irinotecan in Treating Children With Refractory Solid Tumors
NCT00004078
COMPLETED
PHASE2
Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors
NCT02015728
UNKNOWN
NA
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
NCT00101270
COMPLETED
PHASE1
Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma
NCT00287976
UNKNOWN
PHASE2
Vinorelbine in Treating Children With Recurrent or Refractory Cancers
NCT00003234
COMPLETED
PHASE2
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
NCT00020150
COMPLETED
PHASE1
Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma
NCT02914405
ACTIVE_NOT_RECRUITING
PHASE1
Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma
NCT06620302
RECRUITING
PHASE1/PHASE2
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
NCT00331643
COMPLETED
PHASE2
Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors
NCT01141244
COMPLETED
PHASE1
Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours
NCT00918320
COMPLETED
PHASE2
Irinotecan Combination Chemotherapy for Refractory or Relapsed Brain Tumor in Children and Adolescents
NCT01535183
UNKNOWN
PHASE2
Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma
NCT00002802
COMPLETED
PHASE3
Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
NCT04308330
UNKNOWN
PHASE1
Efficacy and Safety of Anlotinib, Irinotecan and Temozolomide in the Treatment of Refractory or Recurrent Neuroblastoma in Children: an Open, Single Arm, Single Center, Phase II Clinical Study
NCT04842526
UNKNOWN
PHASE2
Study of MLN8237 in Combination With Irinotecan and Temozolomide
NCT01601535
COMPLETED
PHASE1/PHASE2